Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
International Journal of Infectious Diseases · 2024
DOI: 10.1016/j.ijid.2024.107149 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Infectious Diseases, 2024. Verfasst von Eric Yuk Fai Wan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Hospitalization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVES: To evaluate the difference between BNT162b2 and CoronaVac in vaccine effectiveness and safety. METHODS: This target trial emulation study included individuals aged ≥12 during 2022. Propensity score matching was applied to ensure group balance. The Cox proportional hazard model was used to compare the effectiveness outcomes including COVID-19 infection, severity, 28-day hospitalization, and 28-day mortality after infection. Poisson regression was used for safety outcomes including 32 adverse events of special interests between groups. RESULTS: A total of 639,818 and 1804,388 individuals were identified for the 2-dose and 3-dose comparison, respectively. In 2-dose and 3-dose comparison, the hazard ratios (95% confidence intervals [CI]) were 0.844 [0.833-0.856] and 0.749 [0.743-0.755] for COVID-19 infection, 0.692 [0.656-0.731] and 0.582 [0.559-0.605] for hospitalization, 0.566 [0.417-0.769] and 0.590 [0.458-0.76] for severe COVID-19, and 0.563 [0.456-0.697] and 0.457 [0.372-0.561] for mortality for BNT162b2 recipients versus CoronaVac recipients, respectively. Regarding safety, 2-dose BNT162b2 recipients had a significantly higher incidence of myocarditis (incidence rate ratio [IRR] [95% CI]: 8.999 [1.14-71.017]) versus CoronaVac recipients, but the difference was insignificant in 3-dose comparison (IRR [95% CI]: 2.000 [0.500-7.996]). CONCLUSION: BNT162b2 has higher effectiveness among individuals aged ≥12 against COVID-19-related outcomes for SARS-CoV-2 omicron compared to CoronaVac, with almost 50% lower mortality risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health (D(2…
- Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science and Technology Park, Hong Kong SAR, China; Advanced Data Analytics for Medical Science (ADAMS) Limited, Hong Kong SAR, China; School of Nursing, Li Ka…
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Zitieren
APA
Wan, E. Y. F., Wang, B., Lee, A. L., Zhou, J., Chui, C. S. L., Lai, F. T. T., Li, X., Wong, C. K. H., Hung, I. F. N., Lau, C. S., Chan, E. W. Y., & Wong, I. C. K. (2024). Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation. International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2024.107149
Vancouver
Wan EYF, Wang B, Lee AL, Zhou J, Chui CSL, Lai FTT, et al. Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation. International Journal of Infectious Diseases. 2024. doi:10.1016/j.ijid.2024.107149
BibTeX
@article{Wan2024,
author = {Wan, Eric Yuk Fai and Wang, Boyuan and Lee, Amanda Lauren and Zhou, Jiayi and Chui, Celine Sze Ling and Lai, Francisco Tsz Tsun and Li, Xue and Wong, Carlos King Ho and Hung, Ivan Fan Ngai and Lau, Chak Sing and Chan, Esther Wai Yin and Wong, Ian Chi Kei},
title = {Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation},
journal = {International Journal of Infectious Diseases},
year = {2024},
doi = {10.1016/j.ijid.2024.107149}
}
EUVIMED